[Exercise-induced asthma in children and oral terbutaline. A dose-response relationship study].
We wanted to assess the protective effects on exercise-induced asthma as well as the clinical efficacy and safety of increasing doses of a new sustained-release formulation of terbutaline sulphate in 17 asthmatic children aged 6-12 years (mean 9 years). Placebo, 2, 4, and 6 mg terbutaline were given b.i.d. for 14 days in a randomized, double-blind, cross-over design. At the end of each two week period, an exercise test was performed and plasma terbutaline was measured. Compared with placebo, no significant effect was seen on asthma symptoms monitored at home, or on exercise-induced asthma. The percentage falls in FEV1 after the exercise test were 36, 35, 27 and 28%, after placebo, 4, 8 and 12 mg terbutaline/day, respectively. A small but statistically significant dose-related increase was seen in morning and evening peak expiratory flow (PEF) recordings. It is concluded that continuous treatment, even with high doses or oral terbutaline, does not offer clinically useful protection against exercise-induced asthma.
Hertz
B
B
Børneafdelingen, Viborg Sygehus.
Fuglsang
G
G
Holm
E B
EB
D000284:Administration, Oral; D001250:Asthma, Exercise-Induced / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D003430:Cross-Sectional Studies; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D013726:Terbutaline / Q000008:administration & dosage* / Q000097:blood
D003692:Delayed-Action Preparations; D013726:Terbutaline
Anstrengelsesudløst astma hos børn og oral terbutalin. Et dosis-respons-studie.